Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors. Read more about Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors.
Type and duration of exogenous hormone use affects breast cancer histology. Read more about Type and duration of exogenous hormone use affects breast cancer histology.
Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement. Read more about Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement.
Clinical Experience With Mammary Ductoscopy. Read more about Clinical Experience With Mammary Ductoscopy.
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Read more about Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
The effect of sentinel node tumor burden on non-sentinel node status and recurrence rates in breast cancer. Read more about The effect of sentinel node tumor burden on non-sentinel node status and recurrence rates in breast cancer.
Thyroid cancer in Graves disease: incidental cancer versus clinical cancer. Read more about Thyroid cancer in Graves disease: incidental cancer versus clinical cancer.
Neoadjuvant hormonal therapy for ductal carcinoma in situ: trial design and preliminary results. Read more about Neoadjuvant hormonal therapy for ductal carcinoma in situ: trial design and preliminary results.
Neoadjuvant chemotherapy for primary breast cancer: lessons learned and opportunities to optimize therapy. Read more about Neoadjuvant chemotherapy for primary breast cancer: lessons learned and opportunities to optimize therapy.
Applying the neoadjuvant paradigm to ductal carcinoma in situ. Read more about Applying the neoadjuvant paradigm to ductal carcinoma in situ.
